SST1 was also found heterodimerized with SST2 in prostate cancer cells; this complex stabilized with a bispecific (SST1/SST2) SRIF agonist, which nevertheless was less efficient than a mono-specific SST1 agonist to produce inhibition of cell proliferation (Ruscica et al., 2010). Here, SSTR1 is linked to prostate carcinoma.